Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Show more
Location: 4800 Montgomery Lane, Bethesda, MD, 20814, United States | Website: https://www.nwbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
331.7M
52 Wk Range
$0.17 - $0.48
Previous Close
$0.22
Open
$0.22
Volume
3,227,618
Day Range
$0.22 - $0.24
Enterprise Value
425.8M
Cash
2.779M
Avg Qtr Burn
-13.51M
Insider Ownership
7.53%
Institutional Own.
0.05%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DCVax-L (personalized immune therapy) Details Glioblastoma | NDA Acceptance for review |